Sansheng Guojian issued a change announcement. The company, Sansheng Pharmaceutical and Shenyang Sansheng jointly granted the licensee Pfizer the exclusive right to develop, produce and commercialize the 707 licensed product project in the licensed area and field. All payments made by the Licensee to the Licensee will be distributed between the Company and Shenyang Sansheng. The License Agreement officially entered into force on July 24, 2025. On October 30, 2025, Pfizer registered two global phase III clinical trials of PD-1/VEGF dual antibody PF-08634404 on the ClinicalTrials.gov website. Since the milestone payment agreed in the License Agreement is subject to a series of specific conditions, there is still uncertainty about the final payment, so investors are kindly requested to pay attention to investment risks.

Sansheng Guojian issued a change announcement. The company, Sansheng Pharmaceutical and Shenyang Sansheng jointly granted the licensee Pfizer the exclusive right to develop, produce and commercialize the 707 licensed product project in the licensed area and field. All payments made by the Licensee to the Licensee will be distributed between the Company and Shenyang Sansheng. The License Agreement officially entered into force on July 24, 2025. On October 30, 2025, Pfizer registered two global phase III clinical trials of PD-1/VEGF dual antibody PF-08634404 on the ClinicalTrials.gov website. Since the milestone payment agreed in the License Agreement is subject to a series of specific conditions, there is still uncertainty about the final payment, so investors are kindly requested to pay attention to investment risks.